View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 20, 2022

Lynk doses first patient in Phase II ankylosing spondylitis drug trial

LNK01001 completed Phase I trials in healthy subjects last year in China and Australia.

Lynk Pharmaceuticals has dosed the first patient with its drug LNK01001 in a Phase II clinical trial for the treatment of ankylosing spondylitis, a chronic inflammatory disorder.

Developed by Lynk, LNK01001 is a Janus Kinase 1 (JAK1) selective inhibitor indicated to treat autoimmune diseases.

The double-blind, randomised Phase II study, which is also placebo-controlled, will evaluate the efficacy as well as safety of the capsules in active ankylosing spondylitis patients.

Lynk Pharmaceuticals chief medical officer Dr Sherry Weigand said: “Ankylosing spondylitis is a chronic, systemic inflammatory disease for which there is no cure, and the clinical demands for an optimal therapy for the disease management are far from being satisfied.

“The results of LNK01001 Phase I clinical research have shown that it is safe and well tolerated, we will accelerate the clinical development of this innovative drug in the hope of bringing a new option to patients with ankylosing spondylitis.”

LNK01001 completed Phase I trials in healthy subjects last year. Phase II clinical trials of the drug are currently underway for the treatment of rheumatoid arthritis.

Peking Union Medical College Hospital and Chinese Academy of Medical Sciences Department of Rheumatology and Immunology director professor Xiaofeng Zeng said: “The preclinical data of LNK01001 shows its therapeutic potential, and we have seen good safety and tolerability in the Phase I studies. I am looking forward to the excellent performance of LNK01001 in the Phase II clinical trial.”

Zeng is also the principal investigator of the study.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy